CEL — Celadon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- £52.13m
- £55.61m
- £0.08m
2019 August 31st | 2020 August 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 16 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.002 | 0.024 | 0.075 |
Cost of Revenue | |||||
Gross Profit | — | — | -2.39 | -4.92 | -5.4 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.206 | 0.187 | 3.49 | 6.87 | 6.75 |
Operating Profit | -0.206 | -0.187 | -3.49 | -6.85 | -6.67 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.191 | -0.175 | -4.8 | -18.1 | -7.52 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.191 | -0.175 | -4.78 | -17.4 | -7.26 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.191 | -0.175 | -4.63 | -17 | -7.14 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.191 | -0.175 | -4.63 | -17 | -7.14 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.029 | -0.028 | -0.093 | -0.28 | -0.108 |
Dividends per Share |